Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 15, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in their interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The material change reported is the increase in shareholdings for three individuals due to the reinvestment of dividends under a Single Company ISA on April 10, 2008. The shares were purchased at a price of GBP 11.13 per ordinary share.
- Mr J S Heslop: Acquired 9 shares.
- Mr E J Gray: Acquired 7 shares.
- Mr A P Witty: Acquired 7 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of the aforementioned share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of GBP 11.13 per ordinary share as of April 10, 2008.
- Confirm the total number of shares acquired by the named directors (23 shares total) through dividend reinvestment.
- Note that this filing does not contain financial performance data for the period.